Latin America PoC Infectious Disease Testing Market Size, Share & Trends Analysis Report By Type (POC Rapid Diagnostic Single Test, POC Rapid Diagnostic Combo Test), By Disease (HIV POC, Malaria), By End-use, By Country, And Segment Forecasts, 2024 - 2030

Latin America PoC Infectious Disease Testing Market Size, Share & Trends Analysis Report By Type (POC Rapid Diagnostic Single Test, POC Rapid Diagnostic Combo Test), By Disease (HIV POC, Malaria), By End-use, By Country, And Segment Forecasts, 2024 - 2030


Latin America PoC Infectious Disease Testing Market Growth & Trends

The Latin America PoC infectious disease testing market size is expected to reach USD 1.1 billion by 2030 and is projected to grow at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. This is driven by several key factors, including high disease prevalence, advancements in diagnostic technology, and supportive regulatory and governmental initiatives. The region continues to face a high burden of infectious diseases such as malaria, tuberculosis (TB), HIV, and neglected tropical diseases. According to the Pan American Health Organization (PAHO), diseases like dengue fever, Zika virus, and Chagas disease are endemic in LATAM, significantly impacting public health and creating a persistent demand for effective diagnostic tools.

Recent developments in diagnostic technology have also played a crucial role. Innovations such as rapid diagnostic tests (RDTs) and molecular assays have enhanced the speed and accuracy of disease detection. For instance, advances in CRISPR-based diagnostics and next-generation sequencing are improving the sensitivity of tests, which is crucial for managing infectious disease outbreaks and providing timely treatment.

Government and international initiatives further drive market growth. In response to the high disease burden, Latin American governments and organizations are implementing strategic health programs. The Brazilian Ministry of Health's "Healthy Brazil" initiative and Colombia's Disease Elimination Initiative are notable examples. These programs focus on improving disease control measures and expanding diagnostic capabilities. Additionally, international organizations like the Global Fund and PAHO are providing financial support and technical assistance, bolstering the infrastructure for disease testing and management.

Latin America PoC Infectious Disease Testing Market Report Highlights
  • Based on type, the PoC rapid diagnostic single test segment dominated the market with more than 70% of revenue share in 2023, driven by its practicality and effectiveness.
  • Based on disease, the COVID-19 segment dominated the market and accounted for 45.8% of the total share in 2023. This dominance is primarily driven by several factors, including the continued impact of the pandemic, high testing demand, and significant advancements in diagnostic technology.
  • Based on end use, the clinics segment held the largest share of 37.5% in 2023. Clinics are pivotal in providing primary healthcare services, including diagnostic testing for infectious diseases.
  • In May 2024, BioPerfectus received approval from Brazil’s ANVISA for its dengue and malaria diagnostic kits. In collaboration with the China CDC, the company developed the Malaria Pf/Pan (HRP2/pLDH) Antigen Rapid Test Kit, supplied to Papua New Guinea, to support local efforts in managing infectious diseases.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Disease
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Latin America
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type
2.2.2. Disease
2.2.3. End Use
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Latin America Point of Care (PoC) Infectious Disease Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High Disease Prevalence
3.2.1.2. Technological Advancements
3.2.1.3. Government and International Initiatives
3.2.2. Market restraint analysis
3.2.2.1. Limited Healthcare Access
3.2.2.2. Regulatory and Approval Challenges
3.3. Latin America Point of Care (PoC) Infectious Disease Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Latin America Point of Care (PoC) Infectious Disease Testing Market: Type Estimates & Trend Analysis
4.1. Latin America Point of Care (PoC) Infectious Disease Testing Market: Type Dashboard
4.2. Latin America Point of Care (PoC) Infectious Disease Testing Market: Type Movement Analysis
4.3. Latin America Point of Care (PoC) Infectious Disease Testing Market by Type, Revenue
4.4. POC Rapid Diagnostic Single-test
4.4.1. POC Rapid Diagnostic Single-test market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. POC Rapid Diagnostic Combo-test
4.5.1. POC Rapid Diagnostic Combo-test market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Latin America Point of Care (PoC) Infectious Disease Testing Market: Disease Estimates & Trend Analysis
5.1. Latin America Point of Care (PoC) Infectious Disease Testing Market: Disease Dashboard
5.2. Latin America Point of Care (PoC) Infectious Disease Testing Market: Disease Movement Analysis
5.3. Latin America Point of Care (PoC) Infectious Disease Testing Market Estimates and Forecasts, By Disease, Revenue (USD Million)
5.4. HIV POC
5.4.1. HIV POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Chlamydia & Gonorrhea
5.5.1. Chlamydia & Gonorrhea only market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Adenovirus
5.6.1. Adenovirus market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Rotavirus
5.7.1. Rotavirus market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Norovirus
5.8.1. 5.5. Norovirus market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Shigella
5.9.1. Shigella market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. Dengue
5.10.1. Dengue market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Zika
5.11.1. Zika market estimates and forecasts, 2018 to 2030 (USD Million)
5.12. Typhoid
5.12.1. Typhoid market estimates and forecasts, 2018 to 2030 (USD Million)
5.13. Syphilis
5.13.1. Syphilis market estimates and forecasts, 2018 to 2030 (USD Million)
5.14. Malaria
5.14.1. Malaria market estimates and forecasts, 2018 to 2030 (USD Million)
5.15. Anti-TP (Treponema pallidum)
5.15.1. Anti-TP (Treponema pallidum) market estimates and forecasts, 2018 to 2030 (USD Million)
5.16. Monkeypox
5.16.1. Monkeypox market estimates and forecasts, 2018 to 2030 (USD Million)
5.17. Strep A
5.17.1. Strep A market estimates and forecasts, 2018 to 2030 (USD Million)
5.18. H. pylori
5.18.1. H. pylori market estimates and forecasts, 2018 to 2030 (USD Million)
5.19. HBV POC
5.19.1. HBV POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.20. Pneumonia Or Streptococcus Associated Infections
5.20.1. Pneumonia Or Streptococcus Associated Infections market estimates and forecasts, 2018 to 2030 (USD Million)
5.21. Respiratory Syncytial Virus (RSV) POC
5.21.1. Respiratory Syncytial Virus (RSV) POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.22. HPV POC
5.22.1. HPV POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.23. Influenza/Flu POC
5.23.1. Influenza/Flu POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.24. HCV POC
5.24.1. HCV POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.25. MRSA POC
5.25.1. MRSA POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.26. TB & Drug-resistant TB POC
5.26.1. TB & Drug-resistant TB POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.27. HSV POC
5.27.1. HSV POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.28. COVID-19
5.28.1. COVID-19 POC market estimates and forecasts, 2018 to 2030 (USD Million)
5.29. Other Infectious Diseases
5.29.1. Other Infectious Diseases POC market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Latin America Point of Care (PoC) Infectious Disease Testing Market: End Use Estimates & Trend Analysis
6.1. Latin America Point of Care (PoC) Infectious Disease Testing Market: Sales Indication Dashboard
6.2. Latin America Point of Care (PoC) Infectious Disease Testing Market: Sales Indication Movement Analysis
6.3. Latin America Point of Care (PoC) Infectious Disease Testing Market Estimates and Forecasts, By Sales Indication, Revenue (USD Million)
6.4. Clinics
6.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Hospitals
6.5.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Home
6.6.1. Home market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Assisted Living Healthcare Facilities
6.7.1. Assisted Living Healthcare Facilities market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Laboratory
6.8.1. Laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Latin America Point of Care (PoC) Infectious Disease Testing Market: Regional Estimates & Trend Analysis by Type, Disease, and End Use
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. Latin America
7.3.1. Brazil
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
7.3.2. Argentina
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
7.3.3. Rest of LATAM
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Rest of LATAM market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Vendor Landscape
8.2.1. List of key distributors and channel partners
8.2.2. Key company market share analysis, 2023
8.2.3. InTec Products, Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Assure Tech (Hangzhou) Co., Ltd
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Getein Biotech, Inc.
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Xiamen Biotime Biotechnology Co., Ltd.
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Nantong Egens Biotechnology Co., Ltd.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Xiamen Boson Biotech Co., Ltd.
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. F Hoffman-La Roche Ltd.
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Abbott
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. Thermo Fisher Scientific, Inc.
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Siemens Healthcare AG
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
8.2.13. Becton, Dickinson, and Company (BD)
8.2.13.1. Company overview
8.2.13.2. Financial performance
8.2.13.3. Product benchmarking
8.2.13.4. Strategic initiatives
8.2.14. CTK Biotech
8.2.14.1. Company overview
8.2.14.2. Financial performance
8.2.14.3. Product benchmarking
8.2.14.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings